Answers are grounded in this paper and cite their sources.
Observational analysis reveals ropeginterferon alfa-2b improves hematologic response in patients resistant to hydroxyurea, suggesting better treatment options.
Ropeginterferon alfa-2b demonstrated superior early hematologic efficacy compared with conventional salvage therapies in Korean patients with HU-R/I PV. Extended follow-up is warranted to assess the long-term clinical benefits.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: